MA49971B1 - Vésicules extracellulaires modifiées et leurs utilisations - Google Patents

Vésicules extracellulaires modifiées et leurs utilisations

Info

Publication number
MA49971B1
MA49971B1 MA49971A MA49971A MA49971B1 MA 49971 B1 MA49971 B1 MA 49971B1 MA 49971 A MA49971 A MA 49971A MA 49971 A MA49971 A MA 49971A MA 49971 B1 MA49971 B1 MA 49971B1
Authority
MA
Morocco
Prior art keywords
exosomes
protein
therapeutic
present
luminal surface
Prior art date
Application number
MA49971A
Other languages
English (en)
French (fr)
Other versions
MA49971A (fr
Inventor
Kevin P Dooley
Rane A Harrison
Ke Xu
Damian J Houde
Sonya Haupt
John D Kulman
Douglas E Williams
Russell E Mcconnell
Madeleine Youniss
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70732111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49971(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of MA49971A publication Critical patent/MA49971A/fr
Publication of MA49971B1 publication Critical patent/MA49971B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA49971A 2019-04-17 2019-05-22 Vésicules extracellulaires modifiées et leurs utilisations MA49971B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835430P 2019-04-17 2019-04-17
PCT/US2019/033629 WO2020101740A1 (en) 2018-11-16 2019-05-22 Engineered extracellular vesicles and uses thereof

Publications (2)

Publication Number Publication Date
MA49971A MA49971A (fr) 2020-07-01
MA49971B1 true MA49971B1 (fr) 2022-01-31

Family

ID=70732111

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49971A MA49971B1 (fr) 2019-04-17 2019-05-22 Vésicules extracellulaires modifiées et leurs utilisations

Country Status (28)

Country Link
EP (3) EP4059510B1 (cg-RX-API-DMAC7.html)
JP (2) JP7538795B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210098473A (cg-RX-API-DMAC7.html)
CN (2) CN113286603B (cg-RX-API-DMAC7.html)
AU (1) AU2019378591A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021009231A2 (cg-RX-API-DMAC7.html)
CA (1) CA3119720A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001278A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124897T1 (cg-RX-API-DMAC7.html)
DK (1) DK3672614T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191334A1 (cg-RX-API-DMAC7.html)
ES (1) ES2907967T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220020T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057300T2 (cg-RX-API-DMAC7.html)
IL (1) IL283167A (cg-RX-API-DMAC7.html)
LT (1) LT3672614T (cg-RX-API-DMAC7.html)
MA (1) MA49971B1 (cg-RX-API-DMAC7.html)
MD (1) MD3672614T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021005636A (cg-RX-API-DMAC7.html)
PH (1) PH12021551088A1 (cg-RX-API-DMAC7.html)
PL (1) PL3672614T3 (cg-RX-API-DMAC7.html)
PT (1) PT3672614T (cg-RX-API-DMAC7.html)
RS (1) RS62863B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104956QA (cg-RX-API-DMAC7.html)
SI (1) SI3672614T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200156T1 (cg-RX-API-DMAC7.html)
TW (2) TWI846697B (cg-RX-API-DMAC7.html)
WO (1) WO2020101740A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020215010A1 (en) * 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Compositions of exosomes and aav
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
CN114729356A (zh) * 2019-08-14 2022-07-08 科迪亚克生物科学公司 靶向stat6的细胞外囊泡-aso构建体
EP4013872A1 (en) * 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
EP4013878A1 (en) 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
CN114729327A (zh) 2019-08-14 2022-07-08 科迪亚克生物科学公司 具有stat3反义寡核苷酸的细胞外囊泡
CN114727947A (zh) 2019-09-25 2022-07-08 科迪亚克生物科学公司 细胞外囊泡组合物
EP4034247A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
US20230103726A1 (en) 2019-09-25 2023-04-06 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
JP2022551420A (ja) 2019-09-25 2022-12-09 コディアック バイオサイエンシーズ, インコーポレイテッド 腫瘍を治療するためのil-12提示エクソソームとstingアゴニスト含有エクソソームとの併用
WO2021062057A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Exogenous loading of exosomes via lyophilization
US20230096378A1 (en) 2020-03-12 2023-03-30 Institute For Basic Science Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ, インコーポレイテッド 治療のための細胞外小胞
US20230220068A1 (en) 2020-06-05 2023-07-13 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
CN116209430A (zh) * 2020-08-07 2023-06-02 阿米库斯治疗学公司 囊泡靶向蛋白及其用途
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
US20230366794A1 (en) 2020-09-23 2023-11-16 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
GB202015399D0 (en) * 2020-09-29 2020-11-11 Evox Therapeutics Ltd Engineered extracellular vesicles displaying enhanced pharmacokinetics
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
CN112410304A (zh) * 2020-11-12 2021-02-26 天津大学 一种基因修饰的外泌体及其制备方法和应用
CN112899307A (zh) * 2021-01-28 2021-06-04 苏州大学 GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体的应用
JP2024512236A (ja) * 2021-02-17 2024-03-19 ロンザ セールス アーゲー 細胞外ベシクル-nlrp3アンタゴニスト
CA3207950A1 (en) 2021-02-17 2022-08-25 Kimberly ELLIS Methods of loading extracellular vesicles
CA3213989A1 (en) 2021-04-01 2022-10-06 Conlin O'NEIL Extracellular vesicle compositions
CN114057893B (zh) * 2021-04-26 2022-12-30 苏州大学 一种编码线粒体定位的豆蔻酰化多肽及其制备方法与应用
CN117126886A (zh) * 2022-05-20 2023-11-28 谛邈生物科技(北京)有限公司 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用
JP2025521128A (ja) * 2022-05-24 2025-07-08 シフトバイオ インク. 表面改質された細胞外小胞体及びその治療的使用
WO2024215711A1 (en) * 2023-04-10 2024-10-17 Wake Forest University Health Sciences Modified mammalian vesicles and compositions and methods related thereto
CN116769718A (zh) * 2023-04-21 2023-09-19 南京逸微健华生物科技有限公司 一种工程化细胞外囊泡及用途
WO2024226723A1 (en) * 2023-04-26 2024-10-31 Northwestern University Active loading of biomolecular cargo into engineered vesicles
CN118909084A (zh) * 2023-05-08 2024-11-08 天津外泌体科技有限公司 细胞外囊泡支架蛋白及其应用
EP4644537A1 (en) 2024-04-30 2025-11-05 ConvEyXo Targeted extracellular vesicle
WO2025232431A1 (zh) * 2024-05-08 2025-11-13 天津外泌体科技有限公司 筛选影响细胞外囊泡被摄取的基因的系统和方法
WO2026022863A1 (en) * 2024-07-25 2026-01-29 Christian Medical College Extracellular vesicles and uses thereof for targeted delivery
WO2026055342A1 (en) 2024-09-04 2026-03-12 Arsenal Biosciences, Inc. Synthetic pathway activators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
PT2254586E (pt) 2008-02-22 2015-05-18 Agency Science Tech & Res Partículas de células estaminais mesenquimais
FR2950350B1 (fr) 2009-09-24 2013-12-13 Centre Nat Rech Scient Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
EP3164420A4 (en) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
WO2016138525A1 (en) * 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
WO2016172598A1 (en) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
WO2017117585A1 (en) 2015-12-30 2017-07-06 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
US10617768B2 (en) * 2016-07-12 2020-04-14 Santa Clara University Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins
EP3500244B1 (en) * 2016-08-22 2026-07-08 Lonza Sales AG Methods of suppressing delivery of exosomes to liver and spleen
WO2018112154A1 (en) * 2016-12-15 2018-06-21 Codiak Biosciences, Inc. Methods of measuring exosomes using intrinsic fluorescence
KR20240033086A (ko) 2017-08-25 2024-03-12 코디악 바이오사이언시즈, 인크. 막 단백질을 사용한 치료용 엑소좀의 제조
US20190151456A1 (en) * 2017-11-17 2019-05-23 Codiak Biosciences, Inc. Compositions of Engineered Exosomes and Methods of Loading Luminal Exosome Payloads
WO2020041720A1 (en) * 2018-08-24 2020-02-27 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof

Also Published As

Publication number Publication date
EP4059510B1 (en) 2025-05-21
SG11202104956QA (en) 2021-06-29
HUE057300T2 (hu) 2022-05-28
CA3119720A1 (en) 2020-05-22
JP2022513049A (ja) 2022-02-07
ES2907967T3 (es) 2022-04-27
EP3672614A1 (en) 2020-07-01
EP4059510A1 (en) 2022-09-21
BR112021009231A2 (pt) 2021-08-10
TW202038993A (zh) 2020-11-01
RS62863B1 (sr) 2022-02-28
EA202191334A1 (ru) 2022-02-10
CN113286603A (zh) 2021-08-20
LT3672614T (lt) 2022-04-11
TWI846697B (zh) 2024-07-01
DK3672614T3 (da) 2022-01-10
KR20210098473A (ko) 2021-08-10
PT3672614T (pt) 2022-02-11
JP2024097929A (ja) 2024-07-19
IL283167A (en) 2021-06-30
MD3672614T2 (ro) 2022-04-30
WO2020101740A9 (en) 2021-06-10
TW202438105A (zh) 2024-10-01
MX2021005636A (es) 2021-07-06
JP7538795B2 (ja) 2024-08-22
MA49971A (fr) 2020-07-01
EP4628099A3 (en) 2025-11-19
WO2020101740A1 (en) 2020-05-22
CN121102502A (zh) 2025-12-12
CL2021001278A1 (es) 2022-03-11
AU2019378591A1 (en) 2021-06-17
CY1124897T1 (el) 2023-01-05
SI3672614T1 (sl) 2022-04-29
HRP20220020T1 (hr) 2022-04-01
CN113286603B (zh) 2025-07-22
PH12021551088A1 (en) 2022-01-03
SMT202200156T1 (it) 2022-05-12
EP4059510C0 (en) 2025-05-21
EP4628099A2 (en) 2025-10-08
EP3672614B1 (en) 2021-10-06
PL3672614T3 (pl) 2022-03-07

Similar Documents

Publication Publication Date Title
EA202191334A1 (ru) Сконструированные внеклеточные везикулы и пути их применения
CN113966397A (zh) 人碳酸酐酶2组合物和用于可调调节的方法
JP2021088598A (ja) 免疫療法のための組成物及び方法
Chen et al. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
MA42021A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon à petites cellules et d'autres cancers
JP2018534932A5 (cg-RX-API-DMAC7.html)
MA42073A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA46299B1 (fr) Molécule de polypeptide à double spécificité améliorée
MA49513B1 (fr) Vecteurs viraux recombinants au tropisme modifié et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines
MA41717A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
JP2020511529A (ja) 免疫療法のためのcd19組成物及び方法
EA201992755A1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
MA43075A1 (fr) Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
WO2003106657A3 (en) Wise/sost nucleic acid sequences and amino acid sequences
IL208598A (en) Linkers of human serum albumin and their constituents, kits and drugs containing them, their use in the preparation of a drug for the treatment of proliferative disease, and a method for their preparation
MA43618A1 (fr) Nouveaux peptides, association de peptides en tant que cibles et destinés à être utilisés en immunothérapie contre le cancer de la vésicule biliaire et le cholangiocarcinome et autres cancers
Cocozza et al. Extracellular vesicles and co‐isolated endogenous retroviruses from murine cancer cells differentially affect dendritic cells
GEP20257842B (en) High affinity antibodies targeting tau phosphorylated at serine 413
EA202192891A1 (ru) Гетерологичное введение анти-тау вакцин
MA43482A1 (fr) Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre la leucémie myéloïde aiguë (lma) et d'autres cancers
ZA202302084B (en) Antibody that binds to vegf-a and ang2 and methods of use
MX2023015244A (es) Anticuerpos biespecificos y usos de los mismos.
WO2024086617A3 (en) Ph-dependent anti-cd3 antibodies and methods relating thereto
WO2020225799A3 (en) A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein